Risk of atrial fibrillation in endometrial cancer patients

Česká verze

Authors: D. Münzová ¹ ; P. Bretová ¹ ; M. Pešl ² ; Vít Weinberger ¹ ; Luboš Minář ¹ ; Michal Felsinger ¹
Authors place of work: Gynekologicko-porodnická klinika LF MU a FN Brno ¹; I. interní kardioangiologická klinika FN u sv. Anny v Brně ²
Published in the journal: Ceska Gynekol 2024; 89(6): 439-444
Category: Původní práce
doi: https://doi.org/10.48095/cccg2024439

Summary

Objective: The study aimed to define atrial fibrillation frequency in endometrial cancer patients, identify risk factors, and propose preventive steps for early detection and treatment leading to decreasing cardiovascular risk. Secondly, we aimed to highlight this topic by presenting a systematic literature review. Methodology: Retrospective analysis of endometrial cancer patients treated at the Department of Gynecology and Obstetrics at University Hospital Brno between 2006 and 2023 complemented by a systematic literature review. Results: The incidence of atrial fibrillation in endometrial cancer patients in our study group (1,101 patients) was 10.4%. Overall, 27% of patients suffered from obesity, hypertension, and diabetes, 26% from both hypertension and obesity, and 10% from diabetes and obesity. The incidence of other risk factors and their combination was less than 10%. Conclusion: Endometrial cancer patients are at a higher risk of developing atrial fibrillation compared with the general population. The risk is enhanced by the presence of other common risk factors such as hypertension, diabetes, and obesity.

Keywords:

obesity – endometrial cancer – hypertension – atrial fibrillation – cardiovascular disease – diabetes mellitus

Zdroje

1. Dusek L, Muzik J, Kubasek M et al. Epidemiologie zhoubných nádorů v České republice. Masarykova univerzita 2005. [online]. Dostupné z: http: //www.svod.cz.

2. Felix AS, Lehman A, Foraker RE et al. Risk of cardiovascular disease among women with endometrial cancer compared to cancer-free women in the Women’s Health Initiative. Cancer Epidemiol 2017; 51: 62–67. doi: 10.1016/j.canep.2017.10.009.

3. Soisson S, Ganz PA, Gaffney D et al. Long-term cardiovascular outcomes among endometrial cancer survivors in a large, population-based cohort study. J Natl Cancer Inst 2018; 110 (12): 1342–1351. doi: 10.1016/j.ygyno.2017.12.025.

4. Ward KK, Shah NR, Saenz CC et al. Cardiovascular disease is the leading cause of death among endometrial cancer patients. Gynecol Oncol 2012; 126 (2): 176–179. doi: 10.1016/ j.ygyno.2012.04.013.

5. Farmakis D, Parissis J, Filippatos G. Insights into onco-cardiology: atrial fibrillation in cancer. J Am Coll Cardiol 2014; 63 (10): 945–953. doi: 10.1016/j.jacc.2013.11.026.

6. Parahuleva MS, Kreutz J, Euler G et al. Incidence of atrial fibrillation in postmenopausal women with endometrial cancer. J Clin Med 2021; 10 (2): 266. doi: 10.3390/jcm10020266.

7. Jakobsen CB, Lamberts M, Carlson N et al. Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12 year follow up study. BMC Cancer 2019; 19 (1): 1105. doi: 10.1186/s12885-019-6314-9.

8. Markides V, Schilling RJ. Atrial fibrillation: classification, pathophysiology, mechanisms and drug treatment. Heart 2003; 89 (8): 939–943. doi: 10.1136/heart.89.8.939.

9. McManus DD, Rienstra M, Benjamin EJ. An update on the prognosis of patients with atrial fibrillation. Circulation 2012; 126 (10): e143–e146. doi: 10.1161/CIRCULATIONAHA.112.129759.

10. Amin A, Houmsse A, Ishola A et al. The current approach of atrial fibrillation management. Avicenna J Med 2016; 6 (1): 8–16. doi: 10.4103/2231-0770.173580.

11. Ziaei F, Zaman M, Rasoul D et al. The prevalence of atrial fibrillation amongst heart failure patients increases with age. Int J Cardiol 2016; 214: 410–411. doi: 10.1016/j.ijcard.2016.03.198.

12. Fang MC, Singer DE, Chang Y et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. Circulation 2005; 112 (12): 1687–1691. doi: 10.1161/CIRCULATIONAHA.105.553438.

13. Feinberg WM, Blackshear JL, Laupacis A et al. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995; 155 (5): 469–473.

14. Kassim NA, Althouse AD, Qin D et al. Gender differences in management and clinical outcomes of atrial fibrillation patients. J Cardiol 2017; 69 (1): 195–200. doi: 10.1016/j.jjcc.2016.02.022.

15. Wong JA, Rexrode KM, Sandhu RK et al. Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation. Heart 2017; 103 (24): 1954–1961. doi: 10.1136/heartjnl-2016-311002.

16. Amant F, Moerman P, Neven P et al. Endometrial cancer. Lancet 2005; 366 (9484): 491–505. doi: 10.1016/S0140-6736 (05) 67063-8.

17. Kitson SJ, Evans DG, Crosbie EJ. Identifying high-risk women for endometrial cancer prevention strategies: proposal of an endometrial cancer risk prediction model. Cancer Prev Res (Phila) 2017; 10 (1): 1–13. doi: 10.1158/1940-6207.

18. Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol 2016; 34 (35): 4225–4230. doi: 10.1200/JCO.2016.69.4638.

19. Nevadunsky NS, van Arsdale A, Strickler HD et al. Obesity and age at diagnosis of endometrial cancer. Obstet Gynecol 2014; 124 (2 Pt 1): 300–306. doi: 10.1097/AOG.0000000000000381.

20. Clinton SK, Giovannucci EL, Hursting SD. The World Cancer Research Fund/American Institute for Cancer Research Third Expert Report on Diet, Nutrition, Physical Activity, and Cancer: Impact and Future Directions. J Nutr 2020; 150 (4): 663–671. doi: 10.1093/jn/nxz268.

21. Goudis CA, Korantzopoulos P, Ntalas IV et al. Obesity and atrial fibrillation: a comprehensive review of the pathophysiological mechanisms and links. J Cardiol 2015; 66 (5): 361–369. doi: 10.1016/j.jjcc.2015.04.002.

22. Han J, Zhang L, Guo H et al. Glucose promotes cell proliferation, glucose uptake and invasion in endometrial cancer cells via AMPK/mTOR/S6 and MAPK signaling. Gynecol Oncol 2015; 138 (3): 668–675. doi: 10.1016/j.ygyno.2015.06.036.

23. Staerk L, Sherer JA, Ko D et al. Atrial fibrillation: epidemiology, pathophysiology, and clinical outcomes. Circ Res 2017; 120 (9): 1501–1517. doi: 10.1161/CIRCRESAHA.117.309732.

24. Bohne LJ, Johnson D, Rose RA et al. The association between diabetes mellitus and atrial fibrillation: clinical and mechanistic insights. Front Physiol 2019; 10: 135. doi: 10.3389/fphys.2019.00135.

25. Hirasawa A, Makita K, Akahane T et al. Hypertriglyceridemia is frequent in endometrial cancer survivors. Jpn J Clin Oncol 2013; 43 (11): 1087–1092. doi: 10.1093/jjco/hyt125.

26. Li ZZ, Du X, Guo XY et al. Association between blood lipid profiles and atrial fibrillation: a case-control study. Med Sci Monit 2018; 24: 3903–3908. doi: 10.12659/MSM. 907580.

27. Tadic M, Ivanovic B, Cuspidi C. What do we currently know about metabolic syndrome and atrial fibrillation? Clin Cardiol 2013; 36 (11): 654–662. doi: 10.1002/clc.22163.

28. Aune D, Sen A, Vatten LJ. Hypertension and the risk of endometrial cancer: a systematic review and meta-analysis of case-control and cohort studies. Sci Rep 2017; 7: 44808. doi: 10.1038/srep44808.

29. Mauro E, Lucà F, Tetta C et al. Breast cancer and atrial fibrillation. J Clin Med 2022; 11 (5): 1417. doi: 10.3390/jcm11051417.

30. Aronow WS. Hypertension associated with atrial fibrillation. Ann Transl Med 2017; 5 (23): 457. doi: 10.21037/atm.2017.10.33.

31. Linz D, Gawalko M, Betz K et al. Atrial fibrillation: epidemiology, screening and digital health. Lancet Reg Health Eur 2024; 37: 100786. doi: 10.1016/j.lanepe.2023.100786.

32. Čihák R, Haman L, Táborský M. Doporučené postupy ESC 2016 pro léčbu fibrilace síní formulované ve spolupráci s EACTS. Souhrn dokumentu připravený Českou kardiologickou společností. Cor Vasa 2016; 58 (6): e636–e683. doi: 10.1016/j.crvasa.2016.11.005.

33. Hindricks G, Potpara T, Dagres N et al. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diag- nosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42 (5): 373–498. doi: 10.1093/eurheartj/ehab648.

34. Sabzwari SR, Garg L, Lakkireddy D et al. Ten lifestyle modification approaches to treat atrial fibrillation. Cureus 2018; 10 (5): e2682. doi:

Doručeno/Submitted: 24. 7. 2024

Přijato/Accepted: 30. 7. 2024

MUDr. Petra Bretová, Ph.D.

Gynekologicko-porodnická klinika

LF MU a FN Brno

Jihlavská 20

625 00 Brno

bretova.petra@fnbrno.cz